Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 1, 2012, Pages 26-32

  Kamel Reid, Suzanne ^a,b   Zhang, Tong ^a   Persons, Diane L ^c   Nikiforova, Marina N ^d   Halling, Kevin C ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CETUXIMAB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PANITUMUMAB; RAS PROTEIN;

ARTICLE; COLORECTAL TUMOR; FOOD AND DRUG ADMINISTRATION; GENETIC SCREENING; GENETICS; HUMAN; IMMUNOLOGY; METASTASIS; METHODOLOGY; MOLECULAR DIAGNOSIS; MUTATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; TREATMENT OUTCOME; UNITED STATES;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; GENETIC TESTING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84863401420     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0220-OA     Document Type: Article

References (24)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Version 2.0. Lyon, France: IARC Press; 2004. World Health Organization Cancer Incidence, Mortality, and Prevalence Worldwide Database. IARC Cancer Base Number 5 [Internet].
2. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32(3):437-453.
3. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer. 2005;103(12):2435-2446. (Pubitemid 40800520)
4. Sauders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer. 2006;95(2):131-138. (Pubitemid 44050911)
5. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17): 1757-1765.
6. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med. 2011;154(1):37-49.
7. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med. 2009;133(10):1600-1606.
8. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-1634.
9. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-379. (Pubitemid 351171687)
10. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19(3):508-515. (Pubitemid 351325672)
11. Jennings L, Van Deerlin VM, Gulley ML; College of American Pathologists Molecular Pathology Resource Committee. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133(5):743-755.
12. Human Genome Variation Society. Nomenclature for the description of sequence variants. http://www.hgvs.org/mutnomen. Last modified January 2011. Accessed June 27, 2011.
13. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28(7):1254-1261.
14. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14): 1408-1417.
15. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663-671.
16. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812-1820.
17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer, version 3. 2011. http://www.nccn.org/professionals/ physician-gls/PDF/colon.pdf. Accessed June 27, 2011.
18. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091-2096.
19. Clinical and Laboratory Standards Institute. Method Comparison and Bias Estimation Using Patient Samples: Approved Guidelines. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institutes; 2005. CLSI document EP9-A2.
20. Soulières D, Greer W, Magliocco AM, et al. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol. 2010;1(7)(suppl 1):S31-S40.
21. Commission on Laboratory Accreditation. Molecular Pathology Checklist. Northfield, IL: College of American Pathologists; 2007. Checklist MOL.31590, revised September 27, 2007.
22. Gulley ML, Braziel RM, Halling KC, et al; for Molecular Pathology Resource Committee, College of American Pathologists Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007;131(6):852-863.
23. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104(6):1020-1026.
24. Mariani P, Lae M, Degeorges A, Cacheux W, et al. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res. 2010;30(10):4229-4235.